Perhaps the biggest news out of ASCO came from the phase III TAILORx study, which showed adjuvant endocrine therapy (ET) alone was noninferior to adjuvant ET in combination with chemotherapy for patients with hormone receptor (HR)-positive, HER2-negative, early-stage breast cancer. Patients for whom noninferiority was demonstrated had node-negative disease and an intermediate risk score for distant recurrence. Nine-year rates were similar for patients receiving ET alone and ET plus chemo, including invasive DFS (83.3% vs. 84.3%), and overall survival (93.9% vs. 93.8%). The results from TAILORx, if implemented, may save thousands of women with breast cancer from overtreatment. TAILORx study lead and lead author, Joseph A. Sparano, MD, from Albert Einstein College of Medicine, will be at Miami Breast and leading the conversation on therapy de-escalation!
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma®
New York GU™: 11th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies